Ursodeoxycholic Acid and Long COVID in Steatotic Liver Disease: A Nationwide Cohort Study
Background/aims
Ursodeoxycholic acid (UDCA) downregulates angiotensin-converting enzyme 2, the cellular entry receptor for SARS-CoV-2, and may reduce acute COVID-19 severity. However, it remains unknown...
Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19
BACKGROUND
There is no proven treatment to alleviate symptoms of postacute sequelae of SARS-CoV-2 infection (PASC), despite its substantial public health burden.
OBJECTIVE
To evaluate the efficacy of...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.